Takeda closes South San Francisco R&D site in California restructuring
This article was originally published in Scrip
Executive Summary
Takeda has decided to close a US research site in South San Francisco that was specialising in the discovery of antibody therapeutics, "relocating the most essential antibody and biologics research technologies and staff" to another existing facility in San Diego.
You may also be interested in...
Takeda's Latest Investment Reflects Long-Term Shift In R&D Strategy
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.